How does a GLP-1 work? Understanding the GLP-1 mechanism of action

Weight management is complex. If you’ve been exploring modern weight management options in the UK, you’ve likely run into medications called GLP-1s or GLP-1 agonists. They’re more technically called glucagon-like peptide-1 receptor agonists. No matter what term you’ve seen, they all refer to the same type of weight loss medications, such as Wegovy (semaglutide).

GLP-1 medications have changed the way obesity is treated, helping weight loss and management feel more achievable for patients. But what are they exactly, and what happens after you take one? To answer these questions, it’s important to look at a GLP-1’s mechanism of action, which is the step-by-step process of how a drug works.

Learning about how GLP-1s work (the mechanism of action) can help you understand exactly what’s happening in your body during treatment, why they can be an effective weight loss aid, and empower you to make informed choices about your health.

In this guide, we break down:

• What a GLP-1 is
• How a GLP-1 works inside the human body
• The main weight loss effects of a GLP-1 
• Definitions of common medication terms
• The leading GLP-1 weight loss options in the UK

What is a GLP-1 and how does it work in the body?

GLP-1 stands for glucagon-like peptide-1. It’s a hormone naturally produced by specialised cells in the small intestine shortly after you eat a meal. 

Under normal circumstances, naturally produced GLP-1 travels through the bloodstream and attaches to a specific protein called a GLP-1 receptor. These receptors are found on several organs throughout your body, such as your brain, pancreas and gastrointestinal tract (such as your food pipe, stomach and intestines).

When GLP-1 attaches to a GLP-1 receptor, it lets your body know that you’ve just eaten a meal, activating the GLP-1 pathway. The GLP-1 pathway sends vital signals across your body:

• At the gastrointestinal tract to help control how fast the food leaves your stomach
• At the pancreas to increase insulin and reduce glucagon to manage your blood sugar levels
• At the brain to make you feel full and satisfied

When GLP-1 detaches from the receptor, it’s broken down and the GLP-1 pathway is stopped.

GLP-1 medications are GLP-1 agonists, which are synthetic versions of the naturally occurring GLP-1, such as semaglutide (Wegovy). This means they can fit inside a GLP-1 receptor and trigger the GLP-1 pathway. They also do not break down as quickly as naturally occurring GLP-1, providing a longer lasting effect.

The three main effects of GLP-1 medications

When you take GLP-1 agonists, the way it works (called the mechanism of action) causes three main effects to support weight loss in the brain, the stomach and the pancreas.

1. Calm food cravings in the brain

The hypothalamus is an area of the brain that controls hunger and appetite. When GLP-1 agonists attach to GLP-1 receptors on the hypothalamus, it tells your brain you’re full. This can help you feel more satisfied after your meal, and help you naturally eat less than you need to. 

Many patients describe this as ‘quietening food noise’, which refers to the act of constantly thinking about or craving food.

2. Slow down digestion in the stomach

GLP-1 agonists slow down a process called gastric emptying. This is the speed at which food leaves your stomach. If food leaves your stomach too quickly, you may feel hungry and want to eat something else soon after your meal even if you don’t need to eat again.

By slowing down how fast you digest your food, you can feel fuller sooner during your meals and also stay satisfied for longer after. This can help many patients avoid eating more than they need to and get better at controlling their portions.

3. Regulate blood sugar levels in the pancreas

When you eat food, your pancreas does two things to help maintain your blood sugar levels:

• Increase insulin to lower your blood sugar 
• Decrease glucagon to raise your blood sugar 

Your pancreas carefully increases insulin and decreases glucagon in response to changes in your blood sugar levels from eating. This helps prevent sharp rises or drops in blood sugar. GLP-1 agonists support this regulation.

Clearing up common medical terms: GLP-1 agonist vs GLP-1 antagonist

When searching online for information about weight loss medications, you might have seen terms like ‘GLP-1 inhibitor’ or ‘GLP-1 antagonist’ alongside ‘GLP-1 agonist’. Medically, an ‘inhibitor’ or ‘antagonist’ works in the opposite way to an ‘agonist’. 

Put simply:

• Inhibitors and antagonists block a receptor to prevent a process from happening. This means a GLP-1 inhibitor or GLP-1 antagonist would block a GLP-1 receptor and prevent the GLP-1 pathway from happening.
  
• Agonists attach to a receptor to activate a process. This means a GLP-1 agonist attaches to a GLP-1 receptor and activates the GLP-1 pathway.

Because GLP-1 treatments activate the GLP-1 pathway, they are called GLP-1 agonists, not GLP-1 inhibitors. Understanding this difference is important as it’ll help you understand weight loss treatments during your research.

Examples of GLP-1 agonist medications in the UK

Today, there are several GLP-1 agonist medications for weight loss treatment available with a prescription in the UK. 

• Wegovy injection (semaglutide): A once-weekly injection designed specifically for weight management in patients with obesity. In clinical trials, weekly semaglutide combined with dietary and lifestyle changes helped adults lose 18% of their starting body weight over 72 weeks on average.
  
• Wegovy pill (oral semaglutide): A daily tablet similar to Wegovy injections. In clinical trials, the Wegovy pill helped patients lose an average 13% of their starting body weight over 64 weeks alongside diet and exercise.
  
• Mounjaro (tirzepatide): A once-weekly injection that acts as a GIP/GLP-1 agonist. Unlike Wegovy, Mounjaro activates two pathways to support weight loss: the GLP-1 pathway and the GIP pathway. Research shows patients can lose up to 20% of their starting body weight after 72 weeks at the maximum dose.

GLP-1 agonists to support your weight loss journey

Managing your health is a personal journey and having access to clear medical information can make all the difference. While GLP-1 treatments are prescription-only and may not be suitable for everybody, understanding the science behind how they work is a valuable first step. 

Exploring your treatment options and seeing how they could support your goals empowers you to approach weight loss with realistic expectations and renewed confidence.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine. 2022. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
2. Moiz A, Filion KB, Tsoukas MA, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine. 2025. Available from: https://www.amjmed.com/article/S0002-9343(25)00059-2/fulltext
3. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet. 2025. Available from: https://pubmed.ncbi.nlm.nih.gov/40961952/
4. Wharton S, Lingvay I, Bogdański P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England Journal of Medicine. 2025. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2500969
5. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024. Available from: https://www.nature.com/articles/s41392-024-01931-z